Hims & Hers Health, Inc. (HIMS)
US could take action including fines against Hims after brief Wegovy copy launch
The Trump administration could take action including an injunction or fines against online telehealth company Hims for intending to sell a compounded version of Novo Nordisk's Wegovy weight-loss pill, though its legal options may be curbed by Hims' quick retreat, attorneys and other experts told Reuters.
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
HIMS is scaling its personalized, at-home digital care model with new testosterone, menopause and Labs launches as subscribers near 2.5 million.
Novo Nordisk CEO on Hims Suit, Wegovy Demand and Pricing
Novo Nordisk says more than 246,000 people are now taking its weight-loss pill. CEO Mike Doustdar sits down with Bloomberg's Katie Greifeld to discuss GLP-1 supply, pricing and the company's lawsuit against Hims over alleged obesity drug copycats.
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.
HIMS Selloff Creates De-Risked Entry
HIMS Selloff Creates De-Risked Entry
Why Hims Stock Slid 40% In A Month?
There are two words that can cause a stock to plummet quicker than one can utter semaglutide: FDA warning. This is precisely what transpired with Hims & Hers Health Inc's shares, as Hims & Hers stock (NYSE: HIMS) dropped approximately 34% over the past month due to investor panic triggered by regulatory scrutiny and increasing legal issues.
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $19.33, denoting a -16.05% move from the preceding trading day.
Hims & Hers Health: Don't Fall For The Hysteria
Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are forecast at only 30% of 2025 revenue, with a broader focus on preventative care and platform growth. Recent FDA and Novo Nordisk actions should have limited impact, as HIMS already pulled the oral Wegovy, and the market has overreacted to worst-case scenarios.
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Hims & Hers is scrapping its plan for a knockoff Wegovy weight-loss pill. Here's why
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug Administration threatened to restrict access to the ingredients needed to copy popular weight-loss medications.Hims had said Thursday that it would offer a compounded version of the new Wegovy pill that drugmaker Novo Nordisk just began selling last month. Novo immediately threatened to sue Hims, and then the FDA said Friday that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound.Hims' own website still touted the new semaglutide pill offering Saturday afternoon — hours after it announced on X that it will no longer sell the medicine.
HIMs 22% Collapse Looks Like A ‘Buy The Dip' Moment
Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9.
